GlobeNewswire

Half-year results for 2021: Schweiter reports strong increase in sales and earnings

Share

Ad hoc announcement pursuant to Art. 53 LR

Steinhausen, August 13, 2021 – Schweiter Technologies reported a strong first half in 2021 amid challenging market conditions, posting a double-digit percentage increase in sales and earnings. Group sales rose by 12% year on year to CHF 626.4 million (11% in local currencies). EBITDA was up by 15% to CHF 77.8 million (14% in local currencies). Despite some major increases in raw material costs, the return on sales improved to reach 12.4%. Operating result (EBIT) rose by 18% to CHF 58.3 million (18% in local currencies), while net income grew 29% to CHF 45.5 million.

Schweiter Technologies Group (in CHF million) H1 2021 H1 2020
+ / -
Net sales 626.4 559.5 +12%
EBITDA 77.8 67.9 +15%
as a % of net sales12.4%12.1%
EBIT 58.3 49.3 +18%
Net income 45.5 35.3 +29%

Business performance, first half 2021

3A Composites reported a pleasing performance with a significant increase in both sales and earnings compared with the first half of 2020. All market segments contributed to the growth in revenue.

The most difficult challenges in the first half of 2021 included meeting delivery deadlines as promised in the face of severe bottlenecks among various supply and transport companies, and managing production at a time when projects were being put on hold by customers. Despite the pressure on supply chains, it was possible to maintain supplier and warehouse management systems and guarantee high product availability. The period saw some significant increases in raw material and transport costs, which could be compensated by sales price increases with a certain delay.

The European Display segment benefited from a renewed increase in demand in the areas of digital printing and shop design, while demand for transparent display panels showed signs of returning to normal. The US Display business also reported a tangible increase in demand for traditional applications such as advertising and interior design. The foamboard business of Newell Brands Inc., acquired in September 2020 and since fully integrated into the company, also contributed to the growth in sales – however the result for this reporting period was impacted by the costs of restructuring and integration. Volatile increases in raw material and transport costs in the USA resulted in temporarily reduced profitability, despite higher capacity utilization and ongoing sales price rises.

The Architecture segment was marked by two contrasting trends. While the European and the US Architecture business recorded double-digit sales growth, the Asian Architecture business was affected by lockdown measures in India and project postponements in China and the Middle East. The US Architecture business in particular achieved an excellent result with high revenues.

In the Core Materials segment, the strong momentum of the previous two years was sustained. Firm demand from wind energy and marine customers together with good capacity utilization at the production sites as well as the strong market position of the PET foam and balsa segments – the latter with its own FSC-certified plantations – led to a double-digit percentage increase in revenues and above-average profit growth.

Sales in the Transport segment were only slightly up on the previous year due to ongoing project postponements, but the demand for industrial applications showed a sharp increase.

Outlook

Despite the ongoing challenges relating to raw materials and logistics, the Group anticipates a positive performance in the second half of the year, although income will be lower in comparison with the exceptionally strong baseline of the second half of 2020.

In the Display and Architecture segments and in Transport and Industry, demand is expected to remain firm.

In the Core Materials segment, 3A Composites expects to see a cyclical decline in demand from wind energy customers, especially in China. However, plans by major energy producers to continue to invest heavily in wind power are bolstering the pleasing medium- to long-term outlook of the segment.

The complete Semi-Annual Report for 2021 can be found on our website www.schweiter.com.

A media conference on the 2021 half-year results for analysts, media representatives, and investors will take place at the Marriott Hotel, Neumühlequai 42, Zurich, today at 11.00 a.m.

For further information please contact:
Martin Klöti, CFO
Tel. +41 41 757 77 00, Fax +41 41 757 70 01, martin.kloeti@schweiter.com

Please find the Media release in the PDF attached: 
Media release (PDF)


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)17.9.2021 13:30:00 CEST | Press release

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Resu

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS17.9.2021 13:15:00 CEST | Press release

Mechelen, Belgium;17September 2021;13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced todaythatthe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issueda positive opinion for Jyseleca® (filgotinib), a once-daily, oral, JAK1preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately to severely active UC who have failed conventional therapy or biologics. SELECTION comprised two placebo-controlled induction studies, one in biologic-naive patients and the o

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer17.9.2021 13:10:00 CEST | Press release

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen

Elina Stråhlman appointed as Enento Group’s acting CEO17.9.2021 13:00:00 CEST | Press release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 17 SEPTEMBER 2021 AT 2.00 P.M. EEST Elina Stråhlman appointedas Enento Group’s acting CEO As communicated with a stock exchange release on 21 April 2021, Enento Group Plc’s current CEO Jukka Ruuska has given notice of his resignation from the company no later than 31 October 2021. As announced in July, Jeanette Jäger will start as the new CEO and member of the Executive Management Team on 1 January 2022. Since 2016 she has worked in the Swedish company Bankgirot, first as VP Digital Services and from 2017 as CEO of Bankgirot. Enento Group's Board of Directors has today appointed Elina Stråhlman, the Group’s CFO, as an acting CEO for the interim period from 1 November 2021 to 31 December 2021. ENENTO GROUP PLC For further information: Jukka Ruuska CEO Tel. +358 10 270 7111 Distribution: Nasdaq Helsinki Major media enento.com/investors Enento Group is a Nordic knowledge company powering society with intelligence since 1905. We collect and trans

Fobi Launches Connected Retail Commerce Solution At Industry’s Premier Event For Convenience, Grocers and CPG Brands17.9.2021 12:00:00 CEST | Press release

Fobi CEO Rob Anson and Senior Vice President of Business Development Mike Canevaro to launch new Personalized Digital Receipt Marketing Solution at GroceryShop to be held September 19-22 in Las Vegas, Nevada VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is excited to announce the launch of its latest solution. The Fobi connected retail commerce solution will support real-time POS data connectivity across all banners and channels, in-store, online and mobile to provide retailers and CPG manufacturers with the ability to deliver automated and personalized marketing at scale. PERSONALIZED MARKETING TO EMPOWER CPG BRANDS BY PROVIDING THEM WITH DIRECT ACCESS TO ENGAGE CONSUMERS WITH PROMOTIONS AND CAMPAIGN ACTIVATION MEASUREMENT Fobi will now enable manufacturer brands to gain

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 10:07:00 CEST | Press release

Auction date2021-09-17Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,000Volume bought, SEK mln500Number of bids2Number of accepted bids1Average yield-0.028Lowest accepted yield-0.028Highest yield-0.028% accepted at lowest yield 100.00 Auction date2021-09-17Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 350Volume offered, SEK mln1,750Volume bought, SEK mln750Number of bids5Number of accepted bids1Average yield0.277Lowest accepted yield0.277Highest yield0.277% accepted at lowest yield 100.00

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden17.9.2021 09:30:00 CEST | Pressemelding

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden Riksgälden föreslår inga väsentliga ändringar i riktlinjerna för förvaltningen av statsskulden.Förslaget till riktlinjer för 2022lämnas till Finansdepartementet i dag. Riksgälden ser inte behov av några större ändringar i riktlinjerna efter att de justeringar som gjorts de senaste åren har lett till en mer övergripande styrning av skuldförvaltningen. Därmed har Riksgälden god flexibilitet att hantera stora variationer i statens lånebehov inom de ramar som riktlinjerna ger. Regeringen beslutar om riktlinjerna varje år senast den 15 november. Beslutet fattas efter att Riksgälden har lämnat sitt förslag och Riksbanken har yttrat sig över förslaget. I riktlinjerna fastställs bland annat hur statsskulden ska vara sammansatt och vilken löptid den ska ha. Riktvärden för sammansättning och löptid ligger fast Sammansättning Real kronskuld – andelen ska långsiktigt vara 20 procent av statsskulden.Skuld i utländsk valuta – expone